Active — Not RecruitingNot Applicable

A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.

China700 participantsStarted 2025-01-01

Plain-language summary

To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma). * Contrast-enhanced CT scan was performed preoperatively. Exclusion Criteria: * Pure cystic clear cell renal cell carcinoma * Poor-quality CT images

What they're measuring

CT-based radiomics analysis for benign and malignant tumor differentiation

Timeframe: within 1 month

CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC)

Timeframe: within 1 month

CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC)

Timeframe: within 1 month

Trial details

NCT IDNCT07060248

SponsorSecond Xiangya Hospital of Central South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-06-30

View on ClinicalTrials.gov More Renal Cell Carcinoma (RCC) trials